Insiders Neurogene Inc.

Equities

NGNE

US64135M1053

Market Closed - Nasdaq Other stock markets 01:30:00 26/06/2024 am IST			5-day change	1st Jan Change
31.1 ^USD	-2.05%		+2.57%	+60.47%

18/06	Neurogene Doses First Patient in High-Dose Group of Rett Syndrome Trial	MT
18/06	Neurogene Inc. Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Neurogene Inc. Appoints Donna Cochener as Senior Vice President, General Counsel	22/02	CI
Neurogene Inc. Appoints Julie Jordan as Chief Medical Officer	17/01	CI
Neurogene Names Julie Jordan as Chief Medical Officer	17/01	MT
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer	16/01	CI
Neoleukin Therapeutics, Inc. Appoints Sean Smith as Interim Chief Financial Officer	04/23/04	CI
Neoleukin Therapeutics, Inc. Appoints Donna M. Cochener as the Interim Chief Executive Officer	04/23/04	CI
Neoleukin Therapeutics, Inc. Announces Board Changes	10/23/10	CI
Neoleukin Therapeutics Weighs Potential Sale, Plans to Cut Workforce by 70%; CEO Drachman to Leave	09/23/09	MT
Neoleukin Therapeutics, Inc. Announces Stepping Down of Jonathan Drachman, M.D. as Chief Executive Officer	09/23/09	CI
Neoleukin Therapeutics, Inc. Appoints Donna M. Cochener as General Counsel, Senior Vice President Legal	15/22/15	CI
Neoleukin Therapeutics, Inc. Announces Management Changes	12/22/12	CI
Neoleukin Therapeutics Inc. Announces Executive Changes	02/22/02	CI
Neoleukin Therapeutics, Inc. Announces Resignation of Robert Ho as Corporate Secretary, Effective March 1, 2022	15/22/15	CI
Neoleukin Therapeutics, Inc. Announces Resignation of Holly Vance as General Counsel and Corporate Secretary	19/21/19	CI
Insider Trends: 90-Day Buying Trend Prolonged with Insider Purchase of Neoleukin Therapeutics Stock	08/21/08	MT
Neoleukin Therapeutics Announces Appointment of Priti Patel as Chief Medical Officer	03/21/03	CI
Insider Trends: Insider Acquisition Interrupts 90-Day Trend of Sales at Neoleukin Therapeutics	24/20/24	MT
Neoleukin Therapeutics Appoints Holly K. Vance as General Counsel	20/20/20	CI
Neoleukin Therapeutics, Inc. Announces Appointment of Martin Babler to Board of Directors	10/20/10	CI
Neoleukin Therapeutics, Inc. Announces Board Changes	01/20/01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Insiders Neurogene Inc.

Equities

NGNE

US64135M1053

Insiders

Filters